PSA Versus Imaging Monitoring in mCRPC - Alan Bryce

Monitoring prostate-specific antigen (PSA) vs. imaging monitoring in metastatic castration-resistant prostate cancer (mCRPC)

E. David Crawford

Alan Bryce, MD

Related Content:
Prognostic significance of time to prostate-specific antigen (PSA)

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.